Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
The influence of steroidotherapy in COPD exacerbation on matrix metalloproteinase MMP-9 level in BAL, induced sputum and serum Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Correlation of serum Matrix metalloproteinase-9 and clinico-functional parameters in COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Elevation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in healthy smokers Source: Eur Respir J 2005; 26: Suppl. 49, 105s Year: 2005
Decrease in circulating monocyte metalloproteinase-9 content with increasing severity of pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 5s Year: 2002
Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17A in mouse airways Source: Annual Congress 2004 - Insights into asthma and COPD Year: 2004
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002
Imbalance between serum matrix metalloproteinase-9 and its inhibitor is associated with increased airway wall thickness in uncontrolled asthmatics Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010
Effect of theophylline on matrix metalloproteinase-9 in induced sputum in the elderly patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Serum levels of TIMP-1 and TIMP-2 are elevated in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Could concentration of matrix metalloproteinase-9 in serum of COPD patients change into the basic disease progress and a degree of airway obstruction? Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Increased expression of MMP-2 in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005
Progression of monocrotaline-induced pulmonary hypertension in rats can be monitored by plasma activity of matrix metalloproteinase-2 and plasma levels of tenascin-C and proBNP Source: Eur Respir J 2007; 30: Suppl. 51, 7s Year: 2007
Increased levels of osteopontin in sputum supernatant in patients with COPD Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012
Increased levels of hyaluronan in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 436s Year: 2003